How do you administer Vanco (vancomycin) plus injection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Administer Vancomycin Plus Injection

Vancomycin must be administered intravenously as a diluted solution infused over at least 60 minutes to avoid rapid-infusion-related reactions including hypotension, shock, and cardiac arrest. 1

Route and Rate of Administration

  • Never administer vancomycin as a rapid IV bolus or push - this can cause exaggerated hypotension, shock, and rarely cardiac arrest 1
  • Infuse vancomycin over a minimum of 60 minutes to prevent infusion-related reactions including red man syndrome, hypotension, flushing, erythema, urticaria, and pruritus 2, 1
  • Dilute vancomycin to a concentration of 2.5-5 g/L before administration to minimize thrombophlebitis 2
  • Do not give vancomycin intramuscularly - IM injection causes pain, tenderness, and tissue necrosis 1
  • Ensure secure IV access - extravasation causes tissue necrosis 1
  • Rotate venous access sites to minimize thrombophlebitis 2

Standard Dosing Regimens

For Serious Systemic Infections (Bacteremia, Endocarditis, Pneumonia, Osteomyelitis)

  • Administer 15-20 mg/kg/dose IV every 8-12 hours (not to exceed 2 g per dose) in patients with normal renal function 2
  • Consider a loading dose of 25-30 mg/kg (actual body weight) in critically ill patients with sepsis, meningitis, pneumonia, or infective endocarditis 2
  • Prolong the loading dose infusion to 2 hours and consider premedication with an antihistamine to reduce risk of red man syndrome and anaphylaxis 2
  • Target trough concentrations of 15-20 mcg/mL for serious infections including bacteremia, endocarditis, osteomyelitis, meningitis, pneumonia, and severe skin/soft tissue infections 2

For Uncomplicated Skin/Soft Tissue Infections

  • Administer 1 g IV every 12 hours in patients with normal renal function who are not obese 2
  • Trough monitoring is not required for most patients with skin/soft tissue infections who have normal renal function and are not obese 2

For Fulminant Clostridioides difficile Infection

  • Administer vancomycin 500 mg orally (not IV) four times daily for fulminant CDI with hypotension, shock, ileus, or megacolon 3
  • Add IV metronidazole 500 mg every 8 hours together with oral vancomycin, particularly if ileus is present 3
  • Consider rectal vancomycin 500 mg in 100 mL normal saline every 6 hours if ileus prevents oral administration 3

Therapeutic Drug Monitoring

  • Obtain trough concentrations before the fourth or fifth dose at steady state 2
  • Do not monitor peak vancomycin concentrations - trough levels are the most accurate and practical method to guide dosing 2
  • Mandatory trough monitoring is required for:
    • Serious infections (bacteremia, endocarditis, osteomyelitis, meningitis, pneumonia, severe SSTI) 2
    • Morbidly obese patients 2
    • Patients with renal dysfunction including those on dialysis 2
    • Patients with fluctuating volumes of distribution 2

Renal Dosing Adjustments

  • Dosage modification is imperative in patients with impaired renal function since vancomycin is primarily excreted by the kidneys 1, 4
  • Monitor renal function in all patients receiving vancomycin, especially those with underlying renal impairment or receiving concomitant nephrotoxic drugs 1
  • The risk of acute kidney injury increases as serum levels increase - maintain appropriate trough concentrations 1

For Hemodialysis Patients

  • Administer a 20 mg/kg loading dose infused during the last hour of the dialysis session 2
  • Then give 500 mg during the last 30 minutes of each subsequent dialysis session 2

Pediatric Dosing

  • Administer 15 mg/kg/dose IV every 6 hours in children with serious or invasive disease 2
  • Consider targeting trough concentrations of 15-20 mcg/mL in children with serious infections (bacteremia, endocarditis, osteomyelitis, meningitis, pneumonia, severe SSTI), though efficacy and safety data are limited 2

Critical Safety Considerations

Monitoring for Toxicity

  • Monitor for ototoxicity - vancomycin can cause transient or permanent hearing loss, especially with excessive doses, underlying hearing loss, or concomitant ototoxic agents like aminoglycosides 1
  • Serial auditory function tests may be helpful to minimize ototoxicity risk 1
  • Monitor complete blood count periodically - reversible neutropenia has been reported with prolonged therapy 1
  • Avoid excessively high serum concentrations (>30 mcg/mL) which may be associated with ototoxicity 5, 4

Drug Interactions

  • Monitor renal function closely when combining vancomycin with nephrotoxic drugs including amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin 1
  • Be aware that concomitant anesthetic agents increase the frequency of infusion-related events - consider administering vancomycin as a 60-minute infusion prior to anesthetic induction 2, 1

Common Pitfalls to Avoid

  • Do not use standard doses (500 mg every 6 hours or 1 g every 12 hours) regardless of patient characteristics - dosing must be individualized based on weight, renal function, and infection severity 6
  • Do not delay vancomycin in febrile patients with gram-positive cocci on blood culture - this increases mortality with virulent organisms 3
  • Do not continue vancomycin unnecessarily - de-escalate to appropriate β-lactam therapy when culture results show susceptible organisms 3
  • Stopping the infusion usually results in prompt cessation of infusion-related reactions if they occur 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Vancomycin Use in Clinical Practice

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pharmacokinetics of vancomycin.

The Journal of antimicrobial chemotherapy, 1984

Research

Vancomycin.

Mayo Clinic proceedings, 1977

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.